Adaptive Biotechnologies Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Adaptive Biotechnologies wird ein jährliches Gewinn- und Umsatzwachstum von 22.7% bzw. 18.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 24.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -106.2% betragen.

Wichtige Informationen

22.7%

Wachstumsrate der Gewinne

24.3%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	18.1%
Wachstumsrate der Einnahmen	18.8%
Zukünftige Eigenkapitalrendite	-106.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	07 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Jul 12

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

May 08

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Apr 03

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17

Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Feb 01

Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Nov 17

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Oct 13

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Jul 06

Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

May 05

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Apr 15

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Dec 13

Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system

Oct 11

Adaptive Biotechnologies announces $250M non-dilutive royalty financing

Sep 12

We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Aug 14

Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Apr 29

Adaptive Biotechnologies: Good Buy For Long-Term Investors

Apr 15

Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

Feb 26

We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

Jan 09

Our First Assessment On Adaptive Biotechnologies

Dec 16

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ADPT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	265	-115	-23	-94	6
12/31/2025	207	-152	-54	-128	8
12/31/2024	173	-182	-100	-166	8
6/30/2024	169	-213	-137	-129	N/A
3/31/2024	175	-215	-145	-136	N/A
12/31/2023	170	-225	-167	-156	N/A
9/30/2023	180	-196	-171	-159	N/A
6/30/2023	190	-191	-170	-155	N/A
3/31/2023	184	-195	-195	-179	N/A
12/31/2022	185	-200	-200	-184	N/A
9/30/2022	168	-221	-231	-208	N/A
6/30/2022	160	-232	-241	-209	N/A
3/31/2022	155	-229	-248	-199	N/A
12/31/2021	154	-207	-254	-193	N/A
9/30/2021	147	-190	-241	-179	N/A
6/30/2021	133	-171	-234	-182	N/A
3/31/2021	116	-155	-208	-176	N/A
12/31/2020	98	-146	-168	-150	N/A
9/30/2020	92	-122	-148	-137	N/A
6/30/2020	92	-99	-131	-120	N/A
3/31/2020	93	-82	-115	-105	N/A
12/31/2019	85	-70	194	205	N/A
9/30/2019	78	-62	215	227	N/A
6/30/2019	69	-56	235	245	N/A
3/31/2019	59	-53	243	252	N/A
12/31/2018	56	-46	-39	-32	N/A
12/31/2017	38	-43	N/A	-35	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ADPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ADPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ADPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ADPTDie Einnahmen des Unternehmens (16% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ADPTDie Einnahmen des Unternehmens (16% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ADPT wird voraussichtlich in 3 Jahren unrentabel sein.

Adaptive Biotechnologies Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.9% to US$6.83

Price target decreased by 7.3% to US$6.33

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024

Consensus revenue estimates fall by 21%

Consensus revenue estimates fall by 21%

Consensus revenue estimates fall by 21%

Recent updates

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Senior VP notifies of intention to sell stock

Price target increased by 7.9% to US$6.83

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Adaptive Biotechnologies Corporation to Report Q2, 2024 Results on Aug 01, 2024

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Price target decreased by 7.3% to US$6.33

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

New minor risk - Shareholder dilution

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024

Adaptive Biotechnologies Corporation to Report Q1, 2024 Results on May 07, 2024

Adaptive Biotechnologies Corporation Announces CFO Changes

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024

Insufficient new directors

Co-Founder recently sold US$167k worth of stock

Adaptive Biotechnologies: A Post Earnings Assessment

Consensus revenue estimates fall by 21%

Consensus revenue estimates fall by 21%

Consensus revenue estimates fall by 21%

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Full year 2023 earnings: EPS and revenues miss analyst expectations

Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Adaptive Biotechnologies Corporation to Report Q4, 2023 Results on Feb 14, 2024

Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting

Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Consensus revenue estimates fall by 12%

Price target decreased by 15% to US$10.00

Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023

Price target decreased by 8.0% to US$11.43

Adaptive Biotechnologies Corporation to Report Q3, 2023 Results on Nov 09, 2023

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Adaptive Biotechnologies Corporation Announces Launch of Epic Integration for ClonosEQ

Adaptive Biotechnologies Corporation Announces Executive Changes

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023

Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Insufficient new directors

Chief Financial Officer notifies of intention to sell stock

Adaptive Biotechnologies Corporation Announces Resignation of Leslie Trigg from the Board

New minor risk - Insider selling

Chief Financial Officer recently sold US$272k worth of stock

Adaptive Biotechnologies Highlights New Data At ASCO 2023 and EHA 2023 Underscoring the Clonoseq® Assay's Impact as A Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

Adaptive Biotechnologies Corporation Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

President recently sold US$194k worth of stock

Adaptive Biotechnologies Corporation Provides Revenue Guidance for Full Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Adaptive Biotechnologies Corporation to Report Q4, 2022 Results on Feb 14, 2023

Price target increased to US$13.00

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease in Patients with Diffuse Large B-Cell Lymphoma Using Circulating Tumor DNA

Price target decreased to US$12.07

Chief Commercial Officer of MRD notifies of intention to sell stock

Third quarter 2022 earnings: EPS exceeds analyst expectations

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2022

Price target decreased to US$13.21

Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system

Adaptive Biotechnologies Corporation to Report Q3, 2022 Results on Nov 03, 2022

Adaptive Biotechnologies announces $250M non-dilutive royalty financing

We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Chief Commercial Officer of MRD recently sold US$193k worth of stock

Price target decreased to US$14.58